3 Reasons to Sell FTRE and 1 Stock to Buy Instead

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

FTRE Cover Image

Fortrea trades at $17.93 and has moved in lockstep with the market. Its shares have returned 13.3% over the last six months while the S&P 500 has gained 11.4%.

Is now the time to buy Fortrea, or should you be careful about including it in your portfolio? Get the full breakdown from our expert analysts, it’s free.

Why Do We Think Fortrea Will Underperform?

We’re swiping left on Fortrea for now. Here are three reasons you should be careful with FTRE, plus one stock we’d rather own.

1. Revenue Spiraling Downwards

A company’s long-term sales performance is one signal of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Over the last four years, Fortrea’s demand was weak and its revenue declined by 3.1% per year. This was below our standards and signals it’s a low quality business.

Fortrea Quarterly Revenue

2. Previous Growth Initiatives Have Lost Money

Growth gives us insight into a company’s long-term potential, but how capital-efficient was that growth? A company’s ROIC explains this by showing how much operating profit it makes compared to the money it has raised (debt and equity).

Fortrea’s five-year average ROIC was negative 9.3%, meaning management lost money while trying to expand the business. Its returns were among the worst in the healthcare sector.

Fortrea Trailing 12-Month Return On Invested Capital

3. New Investments Fail to Bear Fruit as ROIC Declines

ROIC, or return on invested capital, is a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity).

Over the last few years, Fortrea’s ROIC has unfortunately decreased significantly. Paired with its already low returns, these declines suggest its profitable growth opportunities are few and far between.

Fortrea Trailing 12-Month Return On Invested Capital

Final Judgment

Fortrea falls short of our quality standards. That said, the stock currently trades at 21.2× forward P/E (or $17.93 per share). At this valuation, there’s a lot of good news priced in - we think there are better opportunities elsewhere. Let us point you toward one of Charlie Munger’s all-time favorite businesses.

Stocks We Would Buy Instead of Fortrea

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  247.23
-2.66 (-1.06%)
AAPL  333.74
+0.48 (0.14%)
AMD  495.76
-5.18 (-1.03%)
BAC  61.27
-0.22 (-0.36%)
GOOG  346.12
-7.69 (-2.17%)
META  646.01
-18.53 (-2.79%)
MSFT  393.82
-7.28 (-1.82%)
NVDA  202.81
-4.59 (-2.21%)
ORCL  126.41
+2.20 (1.77%)
TSLA  380.84
-10.22 (-2.61%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.